CRISPR CMO sells 3,786 shares for RSU taxes
CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported RSU vesting and a related share sale.
Rhea-AI Filing Summary
CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported RSU vesting and a related share sale. On May 28, 10,000 Restricted Stock Units converted into 10,000 Common Shares at $0.00 per share. On May 29, 3,786 Common Shares were sold at $55.62 per share to cover tax withholding, as mandated by the company’s RSU Settlement Policy and described as non-discretionary. Following these transactions, Patel directly held 19,357 Common Shares. The underlying RSU award covers 40,000 shares, with 10,000-share tranches scheduled to vest annually from 2025 through 2028.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Patel Naimish
Role
Chief Medical Officer
Sold
3,786 shs ($211K)
Approx. gross sale proceeds
$211K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares | 3,786 | $55.62 | $211K |
| Exercise | Restricted Stock Units | 10,000 | $0.00 | $0.00 |
| Exercise | Common Shares | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 20,000 contracts (Direct);
Common Shares — 19,357 shares (Direct)
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- F2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- F3. This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.
Key Figures
Shares sold for taxes: 3,786 shares
Sale price per share: $55.62 per share
RSUs converted: 10,000 RSUs
+3 more
6 metrics
Shares sold for taxes
3,786 shares
Common Shares sold at $55.62 on May 29, 2026 to cover tax withholding
Sale price per share
$55.62 per share
Price for 3,786 Common Shares sold on May 29, 2026
RSUs converted
10,000 RSUs
Restricted Stock Units converted into Common Shares on May 28, 2026
Shares held after transactions
19,357 shares
Direct Common Share holdings following May 2026 transactions
RSU award size
40,000 RSUs
Restricted Stock Unit award granted May 28, 2024 over four annual tranches
Remaining RSUs after conversion
20,000 RSUs
Derivative RSU balance reported following 10,000-unit conversion
Key Terms
Restricted Stock Units, RSU Settlement Policy, derivative exercise/conversion, open-market sale
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSU Settlement Policy financial
"This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation"
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did CRISPR Therapeutics (CRSP) CMO report?
CRISPR Therapeutics CMO Naimish Patel reported RSU vesting and a tax-related sale. 10,000 Restricted Stock Units converted into Common Shares, and 3,786 shares were sold to satisfy tax withholding obligations mandated by the company’s RSU Settlement Policy.
What RSU award schedule is disclosed for CRISPR Therapeutics (CRSP) CMO?
The CMO’s RSU award covers 40,000 Common Shares. One-quarter vests on May 28 of each year from 2025 through 2028, creating four 10,000-share tranches with annual vesting over this multi-year period, subject to the award’s standard terms.
What type of securities did the CRSP CMO transact in this Form 4?
The CMO transacted in Common Shares and Restricted Stock Units. 10,000 RSUs were converted into Common Shares, then 3,786 of those shares were sold to satisfy tax withholding requirements associated with the vesting event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
